Publisher
Springer Science and Business Media LLC
Reference18 articles.
1. Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 89(5), 485–491.
2. Blankenship, K., Erickson, C. A., Stigler, K. A., Posey, D. J., & McDougle, C. J. (2010). Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6–17 years. Pediatric Health, 4(4), 375–381. https://doi.org/10.2217/phe.10.45
3. Cohen, D., Raffin, M., Canitano, R., Bodeau, N., Bonnot, O., Périsse, D., Consoli, A., & Laurent, C. (2013). Risperidone or aripiprazole in children and adolescents with autism and/or intellectual disability: A Bayesian meta-analysis of efficacy and secondary effects. Research in Autism Spectrum Disorder, 7(1), 167–175.
4. Fortea, A., Ilzarbe, D., Espinosa, L., Solerdelcoll, M., de Castro, C., Oriolo, G., Sugranyes, G., & Baeza, I. (2018). Long-acting injectable atypical antipsychotic use in adolescents: An observational study. Journal of Child and Adolescent Psychopharmacology, 28(4), 252–257. https://doi.org/10.1089/cap.2017.0096
5. Gopal, S., Xu, H., Bossie, C., Burón, J. A., Fu, D. J., Savitz, A., Nuamah, I., & Hough, D. (2014). Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases. International Journal of Clinical Practice, 68(12), 1514–1522. https://doi.org/10.1111/ijcp.12493